ERBB2 and breast carcinoma: Currently, two categories of anti-HER2 drugs have been approved in breast cancer including monoclonal antibody, which is represented by trastuzumab and pertuzumab, and antibody-drug conjugates (ADC), which is represented by T-DM1 (ado-trastuzumab emtansine).